Skip to main content

Table 1 Datasets and found proportions of diabetes subgroups reported in the literature

From: Machine learning based study for the classification of Type 2 diabetes mellitus subtypes

Reference

Database/study

Origin

N

SAID (%)

MARD (%)

MORD (%)

SIDD (%)

SIRD (%)

[8]

ANDIS

Sweden

8980

6.4

39.1

21.6

17.5

15.3

SDR

1466

10.1

34.4

18.3

20.4

16.8

ANDIU

844

7.6

41.7

21.0

14.6

15.2

DIREVA (newly diagnosed)

878

9.9

47.3

22.8

8.9

11.2

DIREVA (longer-term)

2607

14.7

41.0

19.8

14.0

10.6

[32]

ADOPT

International

4003

4.2

33.8

21.4

20.2

20.4

RECORD

4148

NA

36.6

20.5

23.5

19.4

[33]

GDS

Germany

1105

22.4

34.9

29.2

2.5

11.0

[34]

GDS

Germany

414

21.0

35.0

32.0

3.0

9.0

[36]

Retrospective study

China

14624

6.2

30.9

21.6

24.8

16.6

[37]

Retrospective study

China

1152

4.4

21.4

34.6

20.5

19.0

[9]

NHANES

USA

1758

NA

a39.7

a21.4

a15.0

a23.9

ENSANUT

Mexico

614

NA

15.8

32.2

41.9

10.1

SIGMA

Mexico

1521

NA

16.8

34.3

41.1

7.8

MSC

Mexico

331

NA

13.6

45.0

5.7

35.6

CAIPaDi

Mexico

1608

NA

11.5

39.8

43.0

5.7

[38]

DCS

Netherlands

2953

NA

b48.1

17.6

12.7

21.6

GoDARTS

Scotland

5509

NA

b45.7

19.3

17.3

17.7

ANDIS

Sweden

7478

NA

b51.5

23.2

15.9

9.4

[39]

NHANES

USA

5489

NA

25.6

30.1

23.5

20.8

[35]

GDS

Germany

351

23.0

41.0

25.0

4.0

7.0

[40]

ORIGIN - All

International

7017

3.4

38.1

22.7

22.7

13.0

ORIGIN - European

Europe

3361

3.3

40.9

22.3

17.6

15.8

ORIGIN - Latin American

Latin America

2428

3.8

33.4

24.0

27.7

11.0

[41]

FDEMC

Japan

586

10.2

35.7

25.4

15.4

13.3

  1. a These percentages were recalculated merging results of NHANES cycles III and 1998-2004
  2. b These percentages correspond to the sum of MDH and MD groups as explained by the authors
  3. DB abbreviations. ANDIS all new diabetics in scania, SDR scania diabetes registry, ANDIU all new diabetics in Uppsala, DIREVA diabetes registry Vaasa, ADOPT a diabetes outcome progression trial, RECORD rosiglitazone evaluated for cardiac outcomes and regulation of glycaemia in diabetes, GDS german diabetes study, NHANES national health and nutrition examination survey, ENSANUT encuesta nacional de salud y nutrición, MSC metabolic syndrome cohort, DCS diabetes care system, GoDARTS genetics of diabetes audit and research tayside study, ORIGIN outcome reduction with initial glargine intervention, FDEMC Fukushima diabetes, endocrinology, and metabolism cohort. SAID severe autoimmune diabetes, MARD mild age related diabetes, MORD mild obesity related diabetes, SIDD severe insulin-deficient diabetes, SIRD severe insulin-resistant diabetes